Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RBP-7000

Small molecule · developed by Indivior

Phase 3 Most advanced trial (none active)
1 Registered trials

What is RBP-7000?

RBP-7000 is a subcutaneous formulation of risperidone combined with the ATRIGEL Delivery System, which provides sustained, controlled release of the drug after injection. It is being studied in schizophrenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
risperidone in Atrigel
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Indivior Inc.
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02109562 Phase 3 Schizophrenia Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.